Company news: Baxter and Shire

Share this article:
The FDA's Division of Drug Marketing, Advertising and Communication hit Baxter Healthcare Corporation with a warning letter for a physician brochure for Aralast NP, expressing concern over “your continued violative promotion of your products.” The agency cited “similar violations” for overstatement of efficacy and unsubstantiated claims of superiority in an April 14, 2009 warning letter and a July 7, 2008 untitled letter, and demanded that the company provide in writing a plan for ensuring against violative promotion in the future.

Shire is sponsoring six inflammatory bowel disease (IBD) fellowships that “will provide a year of training in the management of IBD to physicians who recently completed a fellowship in gastroenterology.” The fellowships will be housed at top medical institutions including Ceders-Sinai in LA, Cleveland Clinic, Mayo Clinic, Mount Sinai, the University of California San Francisco and University of Chicago Medical Center.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.